CFB-Targeting siRNA Compounds for Lower-Cost Complement Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for complement-associated diseases, particularly those involving complement factor B (CFB), are limited by high costs and inefficiencies, such as the expensive treatment with eculizumab, and there is a need for more effective and affordable treatments for autoimmune diseases and complement dysfunction disorders.
Innovation Solution
Development of oligomeric compounds, including hairpin RNAs and double-stranded RNAs, that specifically inhibit CFB gene expression through RNA interference, providing pharmaceutical compositions for treating complement-associated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If eculizumab is used to treat complement-associated diseases, then therapeutic effectiveness is achieved, but treatment cost increases significantly
Solution Approach 1:
The patent employs small interfering RNA (siRNA) molecules as disposable, programmable therapeutic agents that can be synthesized at lower cost compared to monoclonal antibodies like eculizumab. These siRNA compounds are designed to be transiently active, degrading after performing their gene-silencing function, which aligns with the principle of using cheap, short-living objects to replace expensive, long-lasting treatments.
Solution Approach 2:
The invention changes the fundamental parameter of therapeutic mechanism from antibody-mediated complement inhibition to RNA interference-based gene silencing. By modifying the molecular approach (from protein to nucleic acid) and the mode of action (from direct inhibition to transcriptional downregulation), the patent achieves comparable therapeutic effectiveness with potentially lower cost structures.
2Reliability
If conventional complement inhibition therapies are used, then disease symptoms are managed, but treatment efficiency is reduced due to high costs and limited options
Solution Approach 1:
The patent segments the complement system into specific gene targets (CFB, C3, Factor H) and develops targeted siRNA molecules for each. This segmentation allows for precise, disease-specific treatments rather than broad complement inhibition, improving treatment efficiency by matching therapeutic intervention to specific pathogenic mechanisms in different complement-associated diseases.
Solution Approach 2:
The siRNA molecules serve as intermediary agents that translate genetic information into therapeutic action. These small RNA compounds mediate the silencing of complement genes through the RNA interference pathway, providing a novel intermediate mechanism between traditional small-molecule drugs and biologics, thereby enhancing treatment efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The oligomeric compounds effectively down-regulate CFB expression, offering a potential therapeutic avenue for autoimmune diseases and complement dysfunction disorders with reduced toxicity and improved efficacy compared to existing treatments.
Implementation Method 1
a first nucleobase sequence that is at least partially complementary to at least a portion of RNA transcribed from an CFB gene
Implementation Method 2
oligomeric compounds, including hairpin RNAs and double-stranded RNAs, that specifically inhibit CFB gene expression through RNA interference
Data Source
AI summary
Nucleic acid products that modulate, in particular interfere with or inhibit CFB gene expression, are provided. The products may be oligomeric compounds that comprise at least a first region of linked nucleosides having at least a first nucleobase sequence that is at least partially complementary to at least a portion o 5 f RNA transcribed from a CFB gene, where the first nucleobase sequence is selected from SEQ ID NOs 1 to 391, 751 and 752, or a fragment thereof.